Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 10/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037411 | 1.00 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23037413 | 1.00 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23037379 | 0.91 | NTRK1 (0.55) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23037381 | 0.91 | NTRK1 (0.55) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23037390 | 0.89 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL31171166 | 0.89 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23037392 | 0.89 | NTRK1 (0.59) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23047212 | 0.86 | NTRK1 (0.54) | NTRK1NTRK3NTRK2 | |
| SCHEMBL23047208 | 0.86 | NTRK1 (0.54) | NTRK1NTRK3NTRK2 | |
| SCHEMBL20359533 | 0.85 | NTRK1 (0.50) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129258-B2 | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof | PRIMEGENE (BEIJING) CO., LTD (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-3786167-B1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE BEIJING CO LTD (CN) | 2024-08-21 | — | — | EP | disclosed |
| US-20220162218-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3786167-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3786167-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162218-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SRC, CYP11B1, LCK | NTRK1 342/4885NTRK3 724/4885NTRK2 614/4885 |
| US-12129258-B2 | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof | SRC, CYP11B1, LCK | NTRK1 342/4885NTRK3 713/4885NTRK2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.